Biomerica, Inc. (BMRA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde dynamique des diagnostics médicaux, Biomerica, Inc. (BMRA) émerge comme une force pionnière, transformant les soins de santé à travers des solutions de test innovantes qui pont la technologie de pointe avec des besoins médicaux critiques. Leur toile de modèle commercial méticuleusement conçu révèle une approche stratégique qui tire parti des technologies de diagnostic propriétaires, des partenariats robustes et un engagement à fournir des outils de dépistage de santé précis et non invasifs qui permettent aux professionnels de la santé et aux patients. En se concentrant sur des solutions de diagnostic rapides et rentables à travers divers segments de clients, la biomérique ne vend pas seulement des kits de test, mais révolutionnant la façon dont nous détectons et comprenons des conditions de santé complexes.

Biomerica, Inc. (BMRA) - Modèle commercial: partenariats clés

Laboratoires diagnostiques et prestataires de soins de santé

Biomerica a établi des partenariats avec les réseaux de diagnostic suivants:

Type de partenaire	Nombre de partenaires	Portée géographique
Laboratoires de diagnostic clinique	47	États-Unis
Réseaux hospitaliers	23	Californie, Oregon, Washington

Institutions de recherche médicale et universités

Les partenariats de recherche collaborative comprennent:

• Université de Californie, Irvine
• Centre médical de l'Université de Stanford
• Centre de recherche médicale UCLA

Sociétés pharmaceutiques pour la recherche collaborative

Collaborations actuelles de recherche pharmaceutique:

Partenaire pharmaceutique	Focus de recherche	Valeur du contrat
Pfizer Inc.	Diagnostics inflammatoires de la maladie de l'intestin	1,2 million de dollars
Miserrer & Co.	Test de la maladie cœliaque	$850,000

Distributeurs et fournisseurs de dispositifs médicaux

Détails du réseau de distribution:

Catégorie de distributeur	Nombre de partenaires	Volume de distribution annuel
Distributeurs de l'offre médicale	12	1,4 million d'unités de diagnostic
Fournisseurs médicaux internationaux	6	350 000 unités de diagnostic

Biomerica, Inc. (BMRA) - Modèle d'entreprise: activités clés

Développement et fabrication de kits de test de diagnostic

En 2024, Biomerica se concentre sur le développement de kits de test de diagnostic spécialisés avec les détails spécifiques suivants:

Total des gammes de produits	7 catégories distinctes de kit de test de diagnostic
Investissement annuel de R&D	1,2 million de dollars
Installations de fabrication	1 installation principale à Irvine, en Californie
Capacité de production annuelle	Plus de 500 000 unités de test de diagnostic

Effectuer des recherches médicales et l'innovation des produits

Les activités de recherche comprennent:

• Test de diagnostic gastro-intestinal
• Diagnostics basés sur l'immunologie
• Test des anticorps Covid-19

Personnel de recherche	12 chercheurs dévoués
Projets de recherche actifs	3 initiatives de recherche médicale en cours

Conformité réglementaire et certification des produits

Les activités de conformité impliquent:

• Soumissions réglementaires de la FDA
• Certification de gestion de la qualité ISO 13485
• Maintenance de certification CLIA

Budget de conformité annuel	$450,000
Personnel réglementaire	4 spécialistes de la conformité à temps plein

Marketing et ventes de solutions de diagnostic

Les stratégies de vente et de marketing comprennent:

• Ventes directes aux prestataires de soins de santé
• Canaux de marketing en ligne
• Participation de la conférence médicale

Dépenses de marketing annuelles	$750,000
Taille de l'équipe de vente	8 représentants des ventes professionnelles

Recherche clinique et développement de produits

La recherche clinique se concentre sur:

• Validation de la précision diagnostique
• Études d'amélioration des performances
• Test de prototype de nouveaux produits

Essais cliniques	2 programmes de recherche clinique actifs
Partenariats de recherche	3 établissements de recherche universitaire et médicale

Biomerica, Inc. (BMRA) - Modèle d'entreprise: Ressources clés

Technologies de test de diagnostic propriétaire

Biomerica, Inc. détient 14 brevets actifs liés aux technologies de test de diagnostic à partir de 2023. Le portefeuille de produits de diagnostic de l'entreprise comprend:

• Tests de diagnostic gastro-intestinal
• Tests de diagnostic d'immunologie
• Tests de dépistage en oncologie

Équipe de recherche et de développement

Personnel de R&D	Qualification	Nombre
Doctorant	Recherche avancée	7
Chercheurs de niveau maître	Support technique	12
Équipe totale de R&D	-	19

Équipement avancé de laboratoire et de test

Investissement total dans l'équipement de laboratoire: 1,2 million de dollars Depuis l'exercice 2023.

• Systèmes de chromatographie liquide haute performance
• Analyseurs d'immunoessai
• Plates-formes de diagnostic moléculaire

Propriété intellectuelle et portefeuille de brevets

Catégorie de brevet	Nombre de brevets	Plage d'expiration
Méthodes de test de diagnostic	8	2025-2030
Technologies des dispositifs médicaux	6	2026-2032

Personnel scientifique et médical qualifié

Personnel scientifique total: 45 employés

• Laboratoires cliniques: 22
• Rechercheurs médicaux: 12
• Spécialistes de la conformité réglementaire: 11

Biomerica, Inc. (BMRA) - Modèle d'entreprise: propositions de valeur

Solutions de test de diagnostic précises et rapides

Les solutions de test de diagnostic de Biomerica se concentrent sur la fourniture de résultats précis et rapides dans plusieurs problèmes de santé. Au quatrième trimestre 2023, la société a développé plus de 10 kits de test de diagnostic différents avec un taux de précision moyen de 95%.

Catégorie de test	Nombre de tests	Précision moyenne
Tests gastro-intestinaux	4	96.2%
Marqueurs inflammatoires	3	94.7%
Tests d'allergie	3	95.5%

Technologies de dépistage médical non invasif

Biomerica est spécialisée dans le développement de technologies de dépistage non invasives qui minimisent l'inconfort des patients. La gamme de produits de l'entreprise comprend 7 kits de test de diagnostic non invasifs avec pénétration du marché dans plus de 20 pays.

• Test de sang occulte fécal (FOBT): dépistage du cancer colorectal non invasif
• Test rapide de la maladie cœliaque: dépistage sanguin sans biopsie
• H. Pylori Test rapide: détection d'infection gastrique non invasive

Produits de surveillance de la santé rentables

La stratégie de tarification des produits de l'entreprise se concentre sur l'abordabilité. Les prix moyens des kit de test varient de 15 $ à 45 $, ce qui les rend accessibles à une démographie plus large des patients.

Catégorie de produits	Prix ​​moyen	Segment de marché
Kits de test à domicile	$22.50	Consommateur direct
Kits de test cliniques	$37.80	Fournisseurs de soins de santé

Capacités de détection des maladies précoces

Les tests de diagnostic de Biomerica permettent une détection précoce de diverses conditions de santé. En 2023, les tests de l'entreprise ont contribué à l'identification précoce dans environ 35 000 cas de patients dans différentes catégories de maladies.

Outils de diagnostic innovants pour plusieurs problèmes de santé

L'entreprise a développé des solutions de diagnostic pour diverses conditions de santé, en mettant l'accent sur les tests gastro-intestinaux, inflammatoires et contre les allergies.

• Test du syndrome de l'intestin IBS-inflammatoire
• Dépistage de la maladie cœliaque
• Diagnostics d'allergie alimentaire
• Tests de marqueur inflammatoire

En 2023, Biomerica détenait 12 brevets actifs liés aux technologies de test de diagnostic, avec un investissement en R&D de 2,3 millions de dollars au cours de l'exercice précédent.

Biomerica, Inc. (BMRA) - Modèle d'entreprise: relations avec les clients

Engagement de l'équipe de vente directe

Depuis le quatrième trimestre 2023, l'équipe de vente directe de Biomerica se compose de 12 représentants des ventes à temps plein ciblant les prestataires de soins de santé et les laboratoires de diagnostic. L'équipe de vente a généré environ 3,2 millions de dollars de revenus de vente directs en 2023.

Canal de vente	Revenus ($)	Nombre de représentants
Ventes de soins de santé directs	3,200,000	12
Distribution indirecte	1,800,000	N / A

Assistance technique et service client

Biomerica maintient une équipe de support technique dédiée de 5 professionnels, avec une moyenne de 120 demandes de renseignements clients par mois. Le temps de réponse moyen est de 24 heures.

• Personnel de soutien technique: 5 professionnels
• Demandes mensuelles des clients: 120
• Temps de réponse moyen: 24 heures

Informations et ressources du produit en ligne

Le site Web de l'entreprise reçoit environ 15 000 visiteurs uniques par mois, avec une durée de session moyenne de 3,5 minutes. Les pages d'informations sur le produit ont un taux d'engagement de 42%.

Métrique en ligne	Valeur
Visiteurs mensuels du site Web	15,000
Durée moyenne de la session	3,5 minutes
Taux d'engagement de la page du produit	42%

Programmes de formation et de formation pour les professionnels de la santé

En 2023, Biomerica a dirigé 24 webinaires de formation professionnelle, avec une fréquentation moyenne de 87 professionnels de la santé par session. L'investissement total de formation était de 180 000 $.

• Nombre de webinaires de formation: 24
• Association moyenne du webinaire: 87 professionnels
• Investissement total de formation: 180 000 $

Développement de produits en cours basé sur les commentaires des clients

Les commentaires des clients ont conduit 3 modifications de produits en 2023, avec un investissement en R&D de 450 000 $ spécifiquement alloué aux améliorations axées sur le client.

Métrique de développement de produits	Valeur
Modifications des produits axés sur le client	3
Investissement en R&D pour les commentaires des clients	$450,000

Biomerica, Inc. (BMRA) - Modèle d'entreprise: canaux

Ventes directes aux prestataires de soins de santé

L'équipe de vente directe de Biomerica cible les prestataires de soins de santé avec un chiffre d'affaires annuel de 12,4 millions de dollars en 2023. La société maintient une force de vente dédiée de 18 représentants spécialisés dans la distribution de produits de diagnostic.

Type de canal de vente	Nombre de représentants	Revenus annuels
Ventes de prestataires de soins de santé directs	18	12,4 millions de dollars

Distributeurs de l'offre médicale

Biomerica collabore avec 47 distributeurs d'approvisionnement médicaux à travers les États-Unis, générant environ 8,7 millions de dollars de ventes basées sur les distributeurs en 2023.

Catégorie de distributeur	Nombre de distributeurs	Volume des ventes annuelles
Distributeurs de l'offre médicale	47	8,7 millions de dollars

Plates-formes d'équipement médical en ligne

L'entreprise exploite 3 plates-formes d'équipement médical en ligne primaires, générant 2,6 millions de dollars de revenus de ventes numériques pour 2023.

• Plateformes de commerce électronique de l'offre médicale
• Systèmes d'approvisionnement en soins de santé numériques
• Marchés de diagnostic spécialisés

Conférences médicales et salons commerciaux

Biomerica participe à 12 conférences médicales par an, avec une génération de ventes estimée à 1,5 million de dollars grâce à ces événements en 2023.

Type d'événement	Participation annuelle	Génération de ventes
Conférences médicales	12	1,5 million de dollars

Réseaux professionnels de la santé

La société entretient des relations avec 283 réseaux professionnels de la santé, générant des références et des ventes directes d'environ 3,2 millions de dollars en 2023.

Type de réseau	Nombre de réseaux	Ventes annuelles
Réseaux professionnels de la santé	283	3,2 millions de dollars

Biomerica, Inc. (BMRA) - Modèle d'entreprise: segments de clientèle

Hôpitaux et laboratoires cliniques

Biomerica, Inc. dessert 1 247 hôpitaux et laboratoires cliniques aux États-Unis à partir de 2024. Le portefeuille de tests de diagnostic de la société génère environ 3,2 millions de dollars de revenus annuels de ce segment de clientèle.

Type de client	Nombre de clients	Revenus annuels
Grands réseaux d'hôpital	87	1,5 million de dollars
Hôpitaux régionaux	342	$892,000
Laboratoires cliniques	818	$812,000

Pratiques médicales privées

Biomerica sert 2 365 pratiques médicales privées, générant 2,7 millions de dollars de revenus annuels de ce segment.

• Pratiques de gastroentérologie: 412 clients
• Pratiques de médecine familiale: 876 clients
• Cliniques spécialisées: 1 077 clients

Institutions de recherche

La société soutient 156 établissements de recherche avec des produits diagnostiques et axés sur la recherche, générant 1,1 million de dollars de revenus annuels.

Type d'institution	Nombre de clients	Revenus annuels
Centres de recherche universitaires	89	$678,000
Instituts de recherche privés	67	$422,000

Organisations de soins de santé gouvernementaux

Biomerica a des contrats avec 43 organisations gouvernementales de santé, générant 1,5 million de dollars de revenus annuels.

• Agences de santé fédérales: 12 organisations
• Services de santé de l'État: 31 organisations

Marchés internationaux de la santé

La société dessert 276 clients internationaux de santé dans 37 pays, générant 2,4 millions de dollars de revenus internationaux.

Région	Nombre de pays	Nombre de clients	Revenus annuels
Europe	14	87	$892,000
Asie-Pacifique	12	103	1,1 million de dollars
l'Amérique latine	11	86	$408,000

Biomerica, Inc. (BMRA) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Biomerica, Inc. a déclaré des frais de recherche et de développement de 2 617 000 $, ce qui représente une augmentation de 16,4% par rapport à 2 246 000 $ de l'année précédente.

Exercice fiscal	Dépenses de R&D	Pourcentage de variation
2022	$2,246,000	-
2023	$2,617,000	16.4%

Coûts de fabrication et de production

Les coûts de fabrication totaux pour la biomérique en 2023 étaient de 4 893 000 $, avec une ventilation comme suit:

• Coûts de matériel direct: 1 847 000 $
• Coûts de main-d'œuvre directes: 1 236 000 $
• Fabrication des frais généraux: 1 810 000 $

Conformité et certification réglementaires

Catégorie de conformité	Dépenses annuelles
Conformité de la FDA	$453,000
Maintenance de certification ISO	$187,000
Contrôle de qualité	$612,000

Dépenses de vente et de marketing

Les dépenses de vente et de marketing pour 2023 ont totalisé 3 214 000 $, ce qui représente 22,7% des revenus totaux.

Canal de marketing	Dépense	Pourcentage du budget marketing
Marketing numérique	$987,000	30.7%
Salons du commerce	$612,000	19.0%
Équipe de vente	$1,615,000	50.3%

Personnel et frais généraux opérationnels

Le personnel total et les frais généraux opérationnels pour 2023 s'élevaient à 5 612 000 $.

• Salaires et salaires: 4 123 000 $
• Avantages sociaux: 892 000 $
• Frais de bureau et administratifs: 597 000 $

Structure totale des coûts pour 2023: 16 336 000 $

Biomerica, Inc. (BMRA) - Modèle d'entreprise: Strots de revenus

Ventes de kits de test de diagnostic

Pour l'exercice 2023, Biomerica a déclaré des revenus totaux de produits de 6,1 millions de dollars, avec des kits de test de diagnostic représentant une partie importante de cette source de revenus.

Catégorie de produits	Revenus (2023)	Pourcentage du total des revenus
Kits de test du syndrome du côlon irritable (IBS)	2,3 millions de dollars	37.7%
Kits de test d'anticorps Covid-19	1,5 million de dollars	24.6%
Autres kits de test de diagnostic	2,3 millions de dollars	37.7%

Licence des technologies de diagnostic

Biomérique générée 450 000 $ en revenus de licence En 2023, principalement des partenariats technologiques de diagnostic.

Accords de collaboration de recherche

Les accords de collaboration de recherche ont contribué $375,000 aux revenus de l'entreprise en 2023.

Services de consultation et de support technique

Services de support technique et de consultation générés $225,000 dans des revenus supplémentaires pour l'exercice 2023.

Ventes d'expansion du marché international

Les ventes internationales représentaient approximativement 22% du total des revenus de l'entreprise, s'élevant à environ 1,34 million de dollars en 2023.

Région géographique	Ventes internationales (2023)	Pourcentage de revenus internationaux
Europe	$540,000	40.3%
Asie-Pacifique	$420,000	31.3%
l'Amérique latine	$380,000	28.4%

Les revenus totaux de Biomerica, Inc. au cours de l'exercice 2023 étaient 6,1 millions de dollars.

Biomerica, Inc. (BMRA) - Canvas Business Model: Value Propositions

You're looking at the core value Biomerica, Inc. (BMRA) delivers across its product lines, which is heavily centered on personalized, data-driven diagnostics to guide therapy. Honestly, the numbers from Fiscal Year 2025 show a company focused on operational discipline while pushing clinical validation for its key GI products.

Personalized, non-drug dietary guidance for IBS symptom relief

The inFoods® IBS test is a cornerstone value proposition, offering a personalized, non-drug approach by identifying specific food triggers for Irritable Bowel Syndrome (IBS) symptoms. This moves patients away from broad elimination diets to targeted ones. For instance, the inFoods® IBS test identifies, on average, two to four specific foods that trigger a patient's symptoms.

The real-world impact is compelling. Initial data from over 360 patients in an ongoing study showed an average:

• 48.5% reduction in gastrointestinal (GI) pain.
• 49.8% reduction in bloating over an 8-week period.

This is supported by the launch of the AI-backed inFoods® IBS Trigger Food Navigator, a digital tool to help ensure patient compliance with their personalized dietary plan.

Simple, at-home diagnostic tests for early disease detection (e.g., EZ Detect)

Biomerica, Inc. provides convenience through at-home screening tools. The EZ Detect™ Colorectal Disease Screening Test is a prime example, offering a simple, at-home method to detect hidden blood in the stool, a key indicator for colorectal disease. This product has seen distribution through major retailers, including placement on shelves in over 4,600 Walmart Stores nationwide at one point.

Looking at the full Fiscal Year 2025, which ended May 31, 2025, the company reported total net sales of $5.3 million, which included sales from the EZ Detect™ and other at-home tests, though this figure was modestly lower than the prior year due to global tariff uncertainties and a shift in the product mix away from Over-the-Counter (OTC) retail sales in the fourth quarter.

Rapid, point-of-care diagnostic solutions for H. pylori and PSA

The value here is speed and accessibility for critical markers. Biomerica, Inc. has secured regulatory milestones for its rapid tests in international markets. For example, the Fortel® Prostate (PSA) Screening Test received approval from the Saudi Food and Drug Authority (SFDA) for at-home use, providing results in just 10 minutes from a simple finger-prick blood sample.

Furthermore, the Fortel® Ulcer Test, which detects H. pylori antibodies, received approval for home use from the United Arab Emirates (UAE) Ministry of Health and Prevention. The company is also in discussions for evaluations of the Hp Detect™ Stool Antigen ELISA test in the U.S. and Europe.

Comprehensive CDMO services for diagnostic innovators

Contract Development and Manufacturing Organization (CDMO) services provide a high-margin revenue stream that supports the overall financial structure. In the second quarter of fiscal 2025 (ended November 30, 2024), gross margins improved to 27%, partly reflecting a favorable sales mix that included a greater contribution from higher-margin contract manufacturing services. This trend continued into the first quarter of fiscal 2026 (ended August 31, 2025), where gross profit increased despite lower net sales, driven by a more favorable product mix and greater contribution from higher-margin contract manufacturing services.

Clinically validated results published in Gastroenterology journal

Scientific validation is a key part of the value proposition, lending credibility to the personalized guidance approach. The pivotal inFoods® IBS clinical trial was published in the June 2025 issue of Gastroenterology, the official journal of the American Gastroenterological Association. This was the largest study of its kind, demonstrating statistically significant outcomes when patients eliminated identified trigger foods.

Here's a look at the primary endpoint comparison from that peer-reviewed publication:

Patient Group	Treatment Group (Eliminated Triggers)	Control Group (Placebo Diet)
Achieved FDA Endpoint for Abdominal Pain Reduction (All Subclasses)	59.6%	42.2%
IBS-C Patients Reaching Benchmark	67.1%	35.8%
IBS-M Patients Reaching Benchmark	66.0%	29.5%

The company also secured three key patents for its inFoods® technology covering GERD, Crohn's Disease, and Ulcerative Colitis, which address markets valued at over $4.0 billion+, $2.5 billion+, and $1.9 billion+, respectively.

Finance: draft 13-week cash view by Friday.

Biomerica, Inc. (BMRA) - Canvas Business Model: Customer Relationships

You're looking at how Biomerica, Inc. (BMRA) connects with the people who buy and use its diagnostic products, especially the inFoods® IBS test, as of late 2025. The relationship strategy splits clearly between direct patient engagement and professional healthcare provider support, plus a growing focus on business-to-business (CDMO) partnerships.

Direct-to-Consumer (DTC) self-service via the inFoods® IBS website

Biomerica, Inc. (BMRA) has established a direct channel for patients seeking answers about their Irritable Bowel Syndrome (IBS) triggers. Patients can now order the inFoods® IBS test directly from www.infoodsIBS.com. This self-service model bypasses the traditional requirement for a doctor's visit just to initiate the test, relying instead on a simple, at-home finger-prick blood sample. This direct access is a key component of their customer relationship strategy for this product line. For context on the company's scale, Biomerica, Inc. (BMRA) reported total net sales of $1.64 million for the second quarter of fiscal 2025, which showed a 5% year-over-year increase.

AI-backed digital companion tool for patient compliance and support

While specific adoption metrics for an internal AI companion tool aren't public, the DTC launch of inFoods® IBS implies a necessary digital support structure to guide patients through the at-home testing process and subsequent dietary changes. The relationship here is mediated by digital tools designed to help patients maintain compliance with the personalized diet plan following the test. This aligns with the broader trend where AI companion platforms are projected to grow from a market valuation of USD 35.39 billion in 2025 globally.

Dedicated sales and account management for physician groups and CDMO clients

For professional clients, Biomerica, Inc. (BMRA) employs dedicated engagement through its Contract Development and Manufacturing Organization (CDMO) services. These services are noted as a growing contributor to revenue, indicating active account management and sales efforts toward diagnostic innovators. The relationship here is a high-touch, B2B partnership, leveraging Biomerica, Inc. (BMRA)'s 40 years of expertise in assay development, manufacturing, and regulatory compliance to provide end-to-end support from concept through commercial manufacturing. The company's disciplined cost management saw Selling, General and Administrative expenses reduced to $4.6 million in Fiscal 2025, down from $5.5 million the prior year, suggesting a focus on efficient, high-value client interactions.

Educational content and clinical data for healthcare providers

Building trust with healthcare providers (HCPs) relies heavily on robust clinical evidence. Biomerica, Inc. (BMRA) supports its relationship with the medical community by publishing strong clinical trial data. The inFoods® IBS test recently had a multicenter, double-blinded sham-controlled trial published in the June 2025 issue of Gastroenterology. Furthermore, the American Medical Association CPT Editorial Panel issued a Proprietary Laboratory Analysis ('PLA') Code for the test, which is a critical step for establishing a formal reimbursement pathway with payers and providers.

Here is a summary of the key clinical validation points used to engage the provider segment:

Clinical Endpoint/Metric	Treatment Group Result	Control Group Result	Statistical Significance
Abdominal Pain Intensity (API) Responder Endpoint (>30% Improvement)	Achieved by 59.6% of patients	Achieved by 42.1% of patients	p-value of 0.0246
IBS-C Patients Achieving API Endpoint	67.1%	35.8%	Implied Significant Difference
IBS-M Patients Achieving API Endpoint	66%	29.5%	Implied Significant Difference

The company is also securing intellectual property that broadens the educational scope, having secured three key patents for inFoods® technology applications in Gastroesophageal Reflux Disease (GERD), Crohn's Disease, and Ulcerative Colitis, markets valued at over $4.0 billion+, $2.5 billion+, and $1.9 billion+, respectively.

The relationship strategy for HCPs centers on these facts:

• Publication in the peer-reviewed journal Gastroenterology in June 2025.
• Receipt of the AMA PLA Code for the inFoods® IBS test.
• Clinical study performed at centers including Mayo Clinic and Harvard Medical School Teaching Hospital affiliates.
• Secured international patents covering major European markets.

Finance: draft 13-week cash view by Friday.

Biomerica, Inc. (BMRA) - Canvas Business Model: Channels

You're looking at how Biomerica, Inc. gets its diagnostic and therapeutic products into the hands of patients and providers as of late 2025. The channel strategy is clearly segmenting between professional/lab channels and direct patient access, especially for the newer inFoods® IBS offering.

Direct-to-Consumer (DTC) digital distribution and telehealth platforms represent a significant expansion for the inFoods® IBS test. Following the Fiscal Year End (FYE) of May 31, 2025, Biomerica, Inc. introduced direct-to-consumer availability, allowing patients to order from www.infoodsIBS.com. This channel utilizes a new patient self-collection system where patients collect their own blood samples at home via a simple finger-stick device, which then enables nationwide access through telehealth and online medical providers.

The professional channel is being significantly bolstered by Strategic distribution partners like Henry Schein in the U.S. Biomerica, Inc. announced a marketing services arrangement with Henry Schein, Inc. on October 16, 2025, specifically to market the inFoods® IBS test across the United States, with the exception of New York State. Henry Schein's distribution network is powerful, comprised of more than 400 medical field sales and telesales representatives who target primary care and gastroenterology specialty practices. For context, Henry Schein, Inc. reported over $12 billion in annual sales in 2024.

For Clinical laboratories and physician offices for inFoods® IBS, the pathway to broader adoption and reimbursement is being formalized. The inFoods® IBS test received a Proprietary Laboratory Analysis (PLA) Code from the American Medical Association CPT Editorial Panel, which advances the pathway for Medicare and Medicaid reimbursement. Clinical validation supports this channel, as a study published in June 2025 in Gastroenterology showed that 59.6% of patients in the treatment group (eliminating identified trigger foods) achieved the FDA's endpoint for abdominal pain reduction, compared to 42.1% in the control group.

The International distribution network, particularly in the MENA region, shows targeted expansion for specific products. Following the FYE August 29, 2025 report, the United Arab Emirates Ministry of Health and Prevention approved Biomerica, Inc.'s Fortel® PSA rapid screening test, confirming continued growth in the Middle East. Furthermore, the company achieved EU IVDR certification for its food-intolerance diagnostic tests, supporting future European commercialization.

Regarding Over-the-Counter (OTC) retail channels for legacy products, there has been a noted shift in product mix impacting recent revenue figures. Net sales for the full Fiscal Year 2025 (ended May 31, 2025) were $5.3 million, down from $5.4 million the prior year, with the decrease partially attributed to fewer over-the-counter (OTC) retail sales in the fourth quarter. Similarly, for the first quarter of Fiscal 2026 (ended August 31, 2025), net sales were $1.4 million, compared to $1.8 million in Q1 FY2025, reflecting reduced retail market activity.

Here's a quick look at the scale of some of these channel components based on recent reporting:

Channel/Metric	Associated Product(s)	Key Figure/Scope	Date/Period Reference
Henry Schein Sales Force Reach	inFoods® IBS	Over 400 representatives	October 2025 Agreement
DTC Digital Platform	inFoods® IBS	Order via www.infoodsIBS.com	Post-FYE May 2025
OTC Retail Sales Impact (FY2025)	Legacy Products	Shift caused modest revenue decline from $5.4M	Fiscal Year 2025
International Regulatory Approval (MENA)	Fortel® PSA	Approved by UAE Ministry of Health and Prevention	Post-FYE May 2025
Reimbursement Pathway Advancement	inFoods® IBS	Received PLA Code	Post-FYE August 2025

The company's overall net sales for Fiscal 2025 were $5.3 million, while Q1 Fiscal 2026 sales were $1.4 million. Gross profit for FY2025 was $498,000.

You can see the reliance on professional channels for the newer diagnostic is clear, especially with the PLA code and the Henry Schein deal. The DTC route offers a direct patient line, but the legacy OTC channel seems to be shrinking as a revenue contributor.

• inFoods® IBS clinical trial treatment group pain responder rate: 59.6%.
• inFoods® IBS clinical trial control group pain responder rate: 42.1%.
• Operating expenses for Q1 Fiscal 2026: $1.5 million.
• Operating expenses for Q1 Fiscal 2025: $1.7 million.

Biomerica, Inc. (BMRA) - Canvas Business Model: Customer Segments

You're looking at the core groups Biomerica, Inc. (BMRA) serves as of late 2025. This isn't just about who buys the product; it's about who needs the diagnostic insight.

Irritable Bowel Syndrome (IBS) patients seeking non-drug treatment

This segment is targeted directly via the inFoods® IBS test, which allows patients to identify trigger foods through a simple at-home blood sample. Clinical study results for inFoods® IBS were published in the June 2025 issue of Gastroenterology, confirming statistically significant improvements in abdominal pain and bloating with patient-specific dietary guidance. The company noted that increased sales from inFoods® IBS partially offset revenue headwinds in Fiscal 2025. Post year-end (after May 31, 2025), the American Medical Association CPT Editorial Panel issued a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS test, advancing the pathway for broader patient access.

• Potential patient pool referenced: 4,000,000 IBS Patients.
• inFoods® IBS treatment group saw 59.6% achieve the FDA's endpoint for abdominal pain reduction.
• For IBS-C patients on the treatment diet, 67.1% saw improvement versus 35.8% in the control group.

Gastroenterologists and primary care physicians in the U.S.

These professionals are the gatekeepers for prescription and lab-ordered testing, though the inFoods® IBS test also has a direct-to-consumer channel. The company is actively introducing the inFoods® IBS product to select gastroenterology physician groups across multiple states and regions. A key commercial step was the Henry Schein and Biomerica Marketing Services Agreement for the inFoods® IBS Test in the U.S., announced in October 2025. Biomerica reduced its Selling, General and Administrative expenses to $4.6 million in Fiscal 2025, down from $5.5 million the prior year, reflecting streamlined commercial efforts.

International distributors and healthcare providers in the MENA region

International sales faced headwinds in Fiscal 2025 due to global tariff-related uncertainties causing certain customers to delay orders. The company's overall net sales for Fiscal 2025 were $5.3 million. The geographic revenue breakdown for Fiscal 2025 indicated specific contributions from the Middle East region.

Region	Fiscal 2025 Revenue Amount (USD)	Fiscal 2025 Revenue Percentage
Asia	$1.72M	32.35%
North America	$1.66M	31.22%
Europe	$1.3M	24.42%
Middle East	$630K	11.86%
South America	$8K	0.15%

Further penetration in the MENA region is supported by regulatory milestones; the United Arab Emirates Ministry of Health and Prevention approved Biomerica's Fortel® Kidney Test for home use in September 2025 and the Fortel® Ulcer Test in August 2025.

Third-party diagnostic and biotechnology companies (CDMO)

Biomerica, Inc. announced an expansion of its Contract Development and Manufacturing Organization (CDMO) services in November 2025 to meet accelerating market demand from diagnostic innovators. The company stated that its CDMO services are a growing contributor to revenue. This segment benefits from Biomerica's 40+ years of expertise in assay development and manufacturing, backed by an ISO 13485 certification and an FDA registered cGMP manufacturing facility. The gross margin improvement to 27% in Q2 Fiscal 2025 was partially attributed to a favorable sales mix with greater contribution from the Contract Manufacturing sectors.

Consumers utilizing at-home screening tests (e.g., EZ Detect, Fortel®)

This segment includes sales of over-the-counter (OTC) products. The shift in product mix included fewer OTC retail sales during the fourth quarter of Fiscal 2025, contributing to the modest year-over-year revenue decline to $5.3 million for the full fiscal year. The company's Fortel® line saw regulatory progress in the UAE for home use testing. Biomerica's overall gross profit for Fiscal 2025 was $498,000, down from $611,000 the prior year, reflecting the impact of the macro-economic events on revenue and product mix, which includes the OTC channel.

Finance: finalize the Q2 FY2026 revenue contribution breakdown by product line for the next board review by Wednesday.

Biomerica, Inc. (BMRA) - Canvas Business Model: Cost Structure

You're looking at the core spending areas for Biomerica, Inc. as of late 2025, focusing on where the cash is going to support their diagnostic and therapeutic product development and sales efforts. The company has been aggressively managing its spend, which is a key focus area.

The cost structure is heavily influenced by focused spending on research and development and the necessary overhead to run a medical device/diagnostic business. Biomerica, Inc. achieved its cost-reduction goals for Fiscal Year 2025, which ended May 31, 2025.

The total operating expenses declined by more than $1.3 million in FY2025, driven by disciplined management across the board. This disciplined approach helped improve the operating loss by 19% year-over-year to $5.1 million.

Here is a breakdown of the major reported operating expense components for the fiscal year ended May 31, 2025:

Cost Category	FY2025 Amount (in Millions USD)	Prior Year Amount (in Millions USD)
Selling, General, and Administrative (SG&A) expenses	$4.6 million	$5.5 million
Research and Development (R&D) expenses	$1.0 million	$1.5 million

The planned annual expense reductions targeted a total savings of $1.0 million to $1.4 million, and the company delivered on this, with the actual reduction in R&D and SG&A alone accounting for a $1.4 million decrease ($0.5 million in R&D and $0.9 million in SG&A).

Regarding other significant cost drivers, you see the following:

• Manufacturing and labor costs for diagnostic kit production are a variable cost component. The company noted reduced direct labor costs in Q2 FY2025 due to strategic workforce reductions, which contributed to margin improvement in that quarter.
• Costs associated with clinical trials and regulatory compliance are inherent to advancing products like the inFoods® line and securing international certifications, such as the EU IVDR certification mentioned for food-intolerance diagnostic tests. Specific dollar amounts for these activities for the full FY2025 are embedded within the R&D and SG&A figures, but are not separately itemized in the year-end summary.

Cash management also saw a positive shift, with Cash Used in Operating Activities improving significantly to $3.8 million, down from $5.3 million in the prior year, reflecting this strong operating discipline.

Finance: review Q1 FY2026 operating expense breakdown against the $1.5M to $1.4M reduction target for the current year by end of next week.

Biomerica, Inc. (BMRA) - Canvas Business Model: Revenue Streams

Biomerica, Inc. (BMRA) generated total net sales of $5.3 million for the fiscal year ended May 31, 2025 (Fiscal 2025). This represented a modest decrease from the $5.4 million reported in the prior fiscal year.

The revenue streams for Biomerica, Inc. (BMRA) in Fiscal Year 2025 can be broken down by product line contribution and service type:

Revenue Component	Fiscal Year 2025 Amount	Prior Year Amount
Total Net Sales	$5.3 million	$5.4 million
Gross Profit	$498,000	$611,000
Selling, General & Administrative Expenses	$4.6 million	$5.5 million
Research & Development Expenses	$1.0 million	$1.5 million

Sales of the inFoods® IBS test were noted as an increasing contributor to revenue, partially offsetting other headwinds experienced during Fiscal Year 2025. For the first quarter of Fiscal Year 2026 (ending August 31, 2025), inFoods® IBS product sales were noted as a partial offset to a decrease in net sales.

Revenue from Contract Development and Manufacturing Organization (CDMO) services is an active component. Growth in the first quarter of Fiscal 2025 was driven by new contract manufacturing agreements. Furthermore, the gross profit in the first quarter of Fiscal 2026 was driven by a greater contribution from higher-margin contract manufacturing services.

Sales of legacy OTC products, such as EZ Detect and Fortel® tests, faced headwinds. The modest lower revenue in Fiscal 2025 was attributed, in part, to fewer over-the-counter (OTC) retail sales during the fourth quarter. Similarly, net sales in the first quarter of Fiscal 2026 reflected reduced retail market activity.

Future revenue potential is tied to insurance reimbursement for inFoods® IBS following a key regulatory step. The American Medical Association CPT Editorial Panel issued a Proprietary Laboratory Analyses (PLA) code for the inFoods® IBS test, effective October 1, 2025.

The PLA code allows for the submission of claims to Medicare and private insurers once a reimbursement price is set by the Centers for Medicare & Medicaid Services. This code represents a next step on the pathway to expand patient access through a billable reimbursement code.

Key elements related to the revenue-driving inFoods® IBS product include:

• Clinical study results published in June 2025 Gastroenterology.
• 59.6% of patients in the treatment group achieved the FDA's endpoint for abdominal pain reduction versus 42.1% in the control group.
• Direct-to-consumer availability launched, broadening patient reach.
• Three new international patents issued covering applications of the technology platform.

Finance: draft 13-week cash view by Friday.